07:00 , Apr 27, 2015 |  BioCentury  |  Politics, Policy & Law

Speed trials

The 2014 West Africa Ebola outbreak is stimulating the fastest vaccine development efforts ever attempted, demonstrating the power of an emerging model that combines the expertise, capabilities and resources of experienced pharma companies, government biomedical...
07:00 , Apr 6, 2015 |  BC Week In Review  |  Clinical News

RVSV-EBOV: Preliminary Phase II data

Preliminary data from >600 healthy volunteers in the Phase II portion of the double-blind, placebo-controlled, Liberian Phase II/III PREVAIL trial showed that a single injection of cAd-EBOZ or VSV-ZEBOV appears to be safe. The...
07:00 , Apr 6, 2015 |  BC Week In Review  |  Clinical News

cAd-EBOZ: Preliminary Phase II data

Preliminary data from >600 healthy volunteers in the Phase II portion of the double-blind, placebo-controlled, Liberian Phase II/III PREVAIL trial showed that a single injection of cAd-EBOZ or VSV-ZEBOV appears to be safe. The...
08:00 , Feb 23, 2015 |  BC Week In Review  |  Clinical News

RVSV-EBOV: Phase II/III started

The National Institute of Allergy and Infectious Diseases (NIAID) began the double-blind, placebo-controlled, Liberian Phase II/III PREVAIL trial to evaluate a single injection of cAd-EBOZ or VSV-ZEBOV in about 28,170 healthy volunteers. cAd-EBOZ is...
08:00 , Feb 23, 2015 |  BC Week In Review  |  Clinical News

cAd-EBOZ: Phase II/III started

The National Institute of Allergy and Infectious Diseases (NIAID) began the double-blind, placebo-controlled, Liberian Phase II/III PREVAIL trial to evaluate a single injection of cAd-EBOZ or VSV-ZEBOV in about 28,170 healthy volunteers. VSV-ZEBOV is...